MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 584338 | Name: Risarestat

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Risarestat, also known as CT 112, has been seen to prevent degeneration of axons and mitochondria of the corneal nerves of diabetic rats.

Chemical Structure

Risarestat
Risarestat
CAS#79714-31-1

Theoretical Analysis

MedKoo Cat#: 584338

Name: Risarestat

CAS#: 79714-31-1

Chemical Formula: C16H21NO4S

Exact Mass: 323.1191

Molecular Weight: 323.41

Elemental Analysis: C, 59.42; H, 6.55; N, 4.33; O, 19.79; S, 9.91

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Risarestat; CT 112
IUPAC/Chemical Name
2,4-Thiazolidinedione, 5-(3-ethoxy-4-(pentyloxy)phenyl)-
InChi Key
CRPGRUONUFDYBG-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H21NO4S/c1-3-5-6-9-21-12-8-7-11(10-13(12)20-4-2)14-15(18)17-16(19)22-14/h7-8,10,14H,3-6,9H2,1-2H3,(H,17,18,19)
SMILES Code
O=C(N1)SC(C2=CC=C(OCCCCC)C(OCC)=C2)C1=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 323.41 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Awata T, Sogo S, Yamagami Y, Yamamoto Y. Effect of an aldose reductase inhibitor, CT-112, on healing of the corneal epithelium in galactose-fed rats. J Ocul Pharmacol. 1988 Fall;4(3):195-201. PubMed PMID: 3143793. 2: Hosotani H, Ohashi Y, Kinoshita S, Matsumoto T, Awata T. Effects of topical aldose reductase inhibitor CT-112 on corneal sensitivity of diabetic rats. Curr Eye Res. 1996 Oct;15(10):1005-7. PubMed PMID: 8921238. 3: Awata T, Sogo S, Yamamoto Y. Effects of aldose reductase inhibitor, CT-112, on sugar alcohol accumulation in corneal epithelium of galactose-fed rats. Jpn J Ophthalmol. 1986;30(3):245-50. PubMed PMID: 3097363. 4: Agnoletti G, Marini D, Bordese R, Villar AM, Gabbarini F. Interventional catheterisation of stenotic or occluded systemic veins in children with or without congenital heart diseases: early results and intermediate follow-up. EuroIntervention. 2012 Mar;7(11):1317-25. doi: 10.4244/EIJV7I11A207. PubMed PMID: 22433195. 5: Ohashi Y, Awata T, Sogo S, Ohira M, Matsuda M, Fukuda M, Manabe R. Intraocular penetration of CT-112, an aldose reductase inhibitor, following topical instillation. J Ocul Pharmacol. 1989 Winter;5(4):325-8. PubMed PMID: 2516866. 6: Yokoi N, Niiya A, Komuro A, Yokogaki S, Naka H, Awata T, Honma Y, Yamada J, Tei M, Kinoshita S. Effects of aldose reductase inhibitor CT-112 on the corneal epithelial barrier of galactose-fed rats. Curr Eye Res. 1997 Jun;16(6):595-9. PubMed PMID: 9192169. 7: Wooley PH, Whalen JD, Dutcher JA, Counts DF. The influence of a peptide sequence from PF-4 (CT-112) on type II collagen-induced arthritis in mice. Inflamm Res. 1995 Aug;44 Suppl 2:S125-6. PubMed PMID: 8548360. 8: Hosotani H, Ohashi Y, Yamada M, Tsubota K. Reversal of abnormal corneal epithelial cell morphologic characteristics and reduced corneal sensitivity in diabetic patients by aldose reductase inhibitor, CT-112. Am J Ophthalmol. 1995 Mar;119(3):288-94. PubMed PMID: 7872388. 9: Wooley PH, Schaefer C, Whalen JD, Dutcher JA, Counts DF. A peptide sequence from platelet factor 4 (CT-112) is effective in the treatment of type II collagen induced arthritis in mice. J Rheumatol. 1997 May;24(5):890-8. PubMed PMID: 9150077. 10: Ohashi Y, Matsuda M, Hosotani H, Tano Y, Ishimoto I, Fukuda M, Manabe R. Aldose reductase inhibitor (CT-112) eyedrops for diabetic corneal epitheliopathy. Am J Ophthalmol. 1988 Mar 15;105(3):233-8. PubMed PMID: 3125744. 11: Jacot JL, Hosotani H, Glover JP, Lois N, Robison WG Jr. Diabetic-like corneal sensitivity loss in galactose-fed rats ameliorated with aldose reductase inhibitors. J Ocul Pharmacol Ther. 1998 Apr;14(2):169-80. PubMed PMID: 9572543. 12: Nakahara M, Miyata K, Otani S, Miyai T, Nejima R, Yamagami S, Amano S. A randomised, placebo controlled clinical trial of the aldose reductase inhibitor CT-112 as management of corneal epithelial disorders in diabetic patients. Br J Ophthalmol. 2005 Mar;89(3):266-8. PubMed PMID: 15722300; PubMed Central PMCID: PMC1772556. 13: Yamamoto Y, Ohtori A. In vitro study of aldose reductase inhibitor concentrations in the lens and inhibitory effect on sugar alcohol accumulation. Curr Eye Res. 1990 May;9(5):421-8. PubMed PMID: 2116955. 14: Tsubota K, Yoshida M, Toda T, Ono M, Kajiwara K, Cheng HM. Aldose reductase inhibition and the phosphorus-31 profile of the intact diabetic rat lens. Ophthalmic Res. 1993;25(6):393-9. PubMed PMID: 8309679. 15: Ohtori A, Yamamoto Y, Tojo KJ. Penetration and binding of aldose-reductase inhibitors in the lens. Invest Ophthalmol Vis Sci. 1991 Jan;32(1):189-93. PubMed PMID: 1898917. 16: Barker SF, Amoah P, Drechsel P. A probabilistic model of gastroenteritis risks associated with consumption of street food salads in Kumasi, Ghana: evaluation of methods to estimate pathogen dose from water, produce or food quality. Sci Total Environ. 2014 Jul 15;487:130-42. doi: 10.1016/j.scitotenv.2014.03.108. Epub 2014 Apr 27. PubMed PMID: 24784738. 17: Terayama H, Inada K, Nakayama H, Yasueda S, Esumi K. Preparation of stable aqueous suspension of a hydrophobic drug with polymers. Colloids Surf B Biointerfaces. 2004 Dec 25;39(4):159-64. PubMed PMID: 15555897. 18: Ohguro N, Matsuda M, Ohashi Y, Fukuda M. Topical aldose reductase inhibitor for correcting corneal endothelial changes in diabetic patients. Br J Ophthalmol. 1995 Dec;79(12):1074-7. PubMed PMID: 8562538; PubMed Central PMCID: PMC505343. 19: Tsubota K, Yamada M. The effect of aldose reductase inhibitor on the corneal epithelium. Cornea. 1993 Mar;12(2):161-2. PubMed PMID: 8500324. 20: Baumann O, Kühnel D, Dames P, Walz B. Dopaminergic and serotonergic innervation of cockroach salivary glands: distribution and morphology of synapses and release sites. J Exp Biol. 2004 Jul;207(Pt 15):2565-75. PubMed PMID: 15201289.

View History

Penicillamine

Penicillamine

Featured